Hepatitis C News and Research

Latest Hepatitis C News and Research

First Edition: July 31, 2014

Today's headlines include reports about the possible hazards that the future might hold for healthcare.gov.

31 Jul 2014

Several insurers report lower profits

WellPoint Inc. on Wednesday said its second-quarter profit slipped as the health insurer recorded higher expenses, masking a boost in revenue and enrollment.

31 Jul 2014

First Edition: July 30, 2014

Today's headlines include a range of health policy headines, including news from Capitol Hill on the Senate confirmation of Robert McDonald to head the VA.

30 Jul 2014

Conjoint Analysis method can show how important different treatment goals are for respondents

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues still need to be clarified.

30 Jul 2014

New pill-only antiviral drug regimens could cure hardest-to-treat hepatitis C

Two new pill-only antiviral drug regimens could provide shorter, more effective treatment options with fewer side effects for the majority of patients infected with hepatitis C, even those most difficult to treat, according to the results of two studies published in The Lancet.

29 Jul 2014

First systematic analysis indicates that about 1 in 3000 donors in England have HEV

The first systematic analysis of hepatitis E virus (HEV) transmission by blood components indicates that about 1 in 3000 donors in England have HEV in their plasma. The findings, published in The Lancet, suggest that around 1200 HEV-containing blood components (eg, red cells, platelets, and fresh frozen plasma) are likely to be transfused every year in England.

29 Jul 2014

New study in recognition of World Hepatitis Day released on Life Sciences Connect

The Intellectual Property and Science business of Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today released a new study in recognition of World Hepatitis Day on Life Sciences Connect, a blog exploring the latest news and trends in Life Sciences and updates on the drug pipeline identifying multiple treatments in development that may serve as potential alternatives to Gilead's Sovaldi, currently priced in the United States at $84,000 for 12 weeks of treatment - $1000 per pill.

28 Jul 2014

First Edition: July 28, 2014

Today's headlines include reports about the deal reached by House and Senate negotiators regarding veterans' health care.

28 Jul 2014

Researchers provide global genotype prevalence estimates for HCV

In one of the largest prevalence studies to date, researchers from the U.K. provide national, regional, and global genotype prevalence estimates for the hepatitis C virus (HCV). Findings published in Hepatology, a journal of the American Association for the Study of Liver Diseases, indicate that genotype 1 is the most prevalent worldwide, with over 83 million patients infected of which one-third reside in East Asia.

28 Jul 2014

Scientists find high proportion of oral bacteria in gut microbiota of liver cirrhosis patients

Scientists from INRA in collaboration with a Chinese team found that the gut microbiota[1] of individuals with liver cirrhosis differ notably from healthy individuals', showing a high proportion of oral bacteria.

26 Jul 2014

Trinidad & Tobago Ministry of Health approves hepatitis C drug telaprevir

The Chemistry, Food & Drugs Division of the Trinidad & Tobago Ministry of Health approved the introduction of Telaprevir to the market, an innovative therapy that significantly increases the cure rate from Hepatitis C, and it is indicated for patients infected with the genotype 1 virus. Telaprevir is available in Trinidad under the trade brand INCIVO®.

26 Jul 2014

Viewpoints: Ryan's 'thoughtful blueprint' to end poverty; GOP challenges after health law ruling

The Republican chairman of the House Budget Committee today released a thoughtful blueprint for overhauling $800 billion worth of U.S. anti-poverty programs.

26 Jul 2014

Trials show immunizations are effective in adults

As kids prepare to head back to school, required immunizations are typically on the to-do list, but getting potentially lifesaving vaccines should not end when adulthood begins, says one University of Alabama at Birmingham infectious diseases expert.

26 Jul 2014

RI Defeats Hepatitis C project aims to eliminate HCV in Rhode Island

Lynn E. Taylor, M.D., director of The Miriam Hospital's HIV/Viral Hepatitis Coinfection program, states in the July, 2014 Rhode Island Medical Journal special edition, "RI Defeats Hep C" that eliminating hepatitis c virus infection (hep c or HCV) is feasible, can provide economic benefits, enhance capacity to address other health challenges, and improve health care disparities.

26 Jul 2014

MedMira adds three new rapid vertical flow tests to Multiplo product line

MedMira, Inc. is expanding its Multiplo product line with the addition of three new multiplex tests that deliver instant, simultaneous, single-cartridge results for syphilis (TP), HIV, and hepatitis C.

26 Jul 2014

Expensive hepatitis drug challenges Medicaid programs' funding

State officials are nervous about how to afford the new medicine, which can run $84,000 for treatment. Also in Medicaid news, federal data show children using emergency room treatment at night or weekends are often on Medicaid.

26 Jul 2014

Galmed reports net loss of $3.9 million for six months ended June 30, 2014

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, today announced financial results for the period ended June 30, 2014.

25 Jul 2014